Ensign Peak Advisors, Inc Alpine Immune Sciences, Inc. Transaction History

Ensign Peak Advisors, Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	BUY	$17.75 - $41.6 $178,707 - $418,828	10,068 Added 7.75%	140,043 $5.55 Million
Q4 2023 Feb 14, 2024	BUY	$8.54 - $20.22 $1.11 Million - $2.63 Million	129,975 New	129,975 $2.48 Million
Q2 2022 Aug 12, 2022	SELL	$6.71 - $9.52 $738,214 - $1.05 Million	-110,017 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$6.41 - $13.89 $237,727 - $515,138	37,087 Added 50.85%	110,017 $987,000
Q3 2021 Nov 12, 2021	BUY	$8.19 - $11.31 $150,286 - $207,538	18,350 Added 33.62%	72,930 $778,000
Q1 2021 May 12, 2021	BUY	$10.02 - $13.92 $185,420 - $257,589	18,505 Added 51.3%	54,580 $579,000
Q4 2020 Feb 12, 2021	BUY	$7.42 - $15.96 $267,676 - $575,757	36,075 New	36,075 $455,000

56.2K

Ticker ALPN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 44,006,700
Description
Alpine Immune Sciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its product pipeline includes ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28...

Get notified when there are updates to the investment portfolio of Ensign Peak Advisors, Inc, based on Form 13F filings with the SEC.

Stay updated on Ensign Peak Advisors, Inc with notifications on news.